| Market Cap | ₹16,436.61 CrMid-cap Pharma |
|---|---|
| TTM P/E | 23.7xSector 41.34x |
| Promoter Holding | 69.87%Stable QoQ |
| Day RSI | 51.37Neutral Zone |
| Order from | DifGen Pharmaceuticals |
| Execution period | Initial launches from FY28 |
Key highlights
- Portfolio includes 20+ differentiated products across injectable, transdermal, and ophthalmic forms
- Collaboration addresses an aggregate US reference market valued at approximately US$5 billion
- Alembic will lead US commercialisation while DifGen handles development and regulatory activities
- Initial product launches are expected to commence from FY28 providing near-term revenue visibility
- Agreement includes First-to-File opportunities and products with limited expected competition
Synergistic Expansion for the US Market
Alembic Pharmaceuticals has broadened its existing relationship with DifGen Pharmaceuticals to establish a robust complex generics pipeline for the United States. This expanded collaboration leverages DifGens research, development, and US-based manufacturing capabilities alongside Alembics established commercial platform. Under the terms of the agreement, DifGen will spearhead development, regulatory filings, and supply chain management, while Alembic is slated to manufacture selected products and manage the entire US commercialisation process.
This strategic move aims to create a capital-efficient pathway to deepen Alembics pipeline and ensure sustainable growth in its high-priority US pharmaceutical business segment.
Portfolio Diversity and Market Access
- Targets 20+ differentiated products including oral and complex dosage forms
- Focuses on transdermal systems and complex injectables with higher entry barriers
- Includes potential Day 1 launches and open First-to-File (FTF) opportunities
- Framework established to progressively build US manufacturing capacity for select forms
- Initial revenue contributions expected to scale progressively starting from FY28
Financial Performance and Strategic Context
This partnership follows a series of strategic moves by Alembic, including a 45:45 joint venture with DifGen Holdings LLC established in June 2026 for the Canadian market and a July 2026 distribution pact with Natco Pharma. These alliances come as Alembic reports strong financial momentum; for the quarter ended June 30, 2026, the company recorded operating revenue of ₹2,149.77 crore, representing a 25.7% year-on-year increase. Despite a 14.6% sequential dip in net profit to ₹173.07 crore, the company maintains a healthy operating margin of 15.44%.
The management had previously guided for R&D expenditure of 8% to 9% of total revenue for FY27.
Strengthening the Complex Generics Franchise
This collaboration further strengthens our complex generics franchise in the US. The portfolio expands Alembic’s exposure to differentiated opportunities, particularly in transdermal systems, complex injectables and other specialised dosage forms. Importantly, the collaboration provides near-term commercial opportunities and access to US manufacturing capabilities.
| Date | Announcement | Amount |
|---|---|---|
| 18 Jul 2026 | Commercial partnership with Natco Pharma Limited for the US marketing and distribution of generic Olaparib TabletsSource: clival.com | – |
| 06 Jun 2026 | Shareholders' agreement with Difgen Holdings LLC to establish a 45:45 joint venture entity (17989377 Canada Inc.) for development and commercialisation in CanadaSource: alembicpharmaceuticals.com | – |
| 28 Jan 2025 | Strategic commercial agreement with Amlan International to introduce poultry health feed additives to the Indian marketSource: alembicpharmaceuticals.com | – |
What to watch next
- Board meeting to approve Q2 FY27 unaudited financial results on November 4, 2026
- Commencement of initial product launches in the US market from FY28
“We believe this is a capital efficient way to deepen our pipeline, strengthen the quality, and sustainability of Alembic’s US business growth and create long-term value for our stakeholders.”
| Share price | ₹836.2 |
|---|---|
| Market capitalisation | ₹16,436.61 Cr |
| Revenue (annual) | ₹7,344.90 Cr |
| Net profit (annual) | ₹674.77 Cr |
| Revenue (latest quarter) | ₹2,149.77 Cr+16.35% vs previous quarter |
| Net profit (latest quarter) | ₹173.07 Cr-14.62% vs previous quarter |
| P/E (TTM) | 23.7×Sector 41.34× |
| Promoter holding | 69.87%0.00% QoQ |
| FII holding | 4.55%Current quarter |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
Exchange filing by Alembic Pharmaceuticals Limited announcing the expansion of its strategic collaboration with DifGen Pharmaceuticals. Market figures from a third-party data provider.
